Cytotoxic therapy revised: exploration of innovative cytotoxic (pro)drugs and antibody-drug conjugates in patient-derived xenograft models of soft tissue sarcoma. KU Leuven
Soft tissue sarcomas (STS) represent a heterogeneous group of rare, malignant tumors of mesenchymal origin, which compromises more than 70 histological subtypes. Despite their extensive histological and molecular variety, the treatment of these patients is rather uniform, driven by the stage of disease at diagnosis instead of rational drug-targeting. While surgery with or without radiotherapy is the mainstay of treatment for patients with ...